Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 8/20 | 0.87 |
| ▸ | CCR5 | P51681 | 13/20 | 0.66 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.55 |
| ▸ | CCR7 | P32248 | 2/20 | 0.55 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL17555185 | 0.99 | CCR2 (0.85) | CCR2CCR5CXCR3CCR7CXCR5 | |
| Hydrochloric Acid SCHEMBL2696183 | 0.99 | CCR2 (0.85) | CCR2CCR5CXCR3CCR7CXCR5 | |
| SCHEMBL13148273 | 0.92 | CCR2 (0.73) | CCR2CCR5 | |
| Hydrochloric Acid SCHEMBL2905488 | 0.91 | CCR2 (0.72) | CCR2CCR5CXCR3CCR7CXCR5 | |
| Iodide SCHEMBL17555182 | 0.91 | CCR2 (0.72) | CCR2CCR5 | |
| SCHEMBL4458590 | 0.90 | CCR2 (0.86) | CCR2CCR5CXCR3CCR7 | |
| Hydrochloric Acid SCHEMBL2696739 | 0.89 | CCR2 (0.85) | CCR2CCR5CXCR3CCR7CXCR5 | |
| Iodide SCHEMBL17555187 | 0.89 | CCR2 (0.85) | CCR2CCR5CXCR3CCR7 | |
| SCHEMBL2692635 | 0.89 | CCR2 (0.70) | CCR2CCR5 | |
| SCHEMBL4452167 | 0.89 | CCR2 (0.87) | CCR2CCR5CXCR3CCR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799824-B2 | Quaternary salt CCR2 antagonists | ORAPHARMA, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090112003-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090112003-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | CCR2, CCR1, CCL11 | CCR2 1/4885CCR5 7/4885CXCR3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.